



Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Guanfacine (Intuniv®)
Indication under review	Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.
Policy No:	APC 132
Date of issue	September 2016
Review Date:	September 2019
Policy Statement: Guanfacine (Intuniv®) is a treatment option for the management of ADHD in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective	
Traffic Light Status	Red
Key Points considered: <ul style="list-style-type: none">• Treatment with guanfacine resulted in clinically meaningful improvement in ADHD symptoms although an effect on social functioning was not consistently seen.• The unwanted effects such as hypotension, bradycardia, sedation, fatigue etc are common and limit tolerability.• The APC have advised that for the first year at least, treatment should be under specialists or until more information is available on the long term safety.	
References: NICE ESNM: Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release, March 2016	
Date taken to APC:	7 th September 2016
Date re-ratified by MOC on Behalf of the Board:	21 st September 2016